Sandalova S, Dal U, Sandalov A. Early Post-Marketing Safety Signals of Anifrolumab in EudraVigilance: A Belimumab-Comparator Disproportionality Analysis. Int J Med Stud [Internet]. 2026 Aug. 18 [cited 2026 Aug. 30];. Available from: https://ijms.info/IJMS/article/view/4785